首页 > 市场调查报告书 > 製药

呼吸器

市场调查报告书

商品编码

1448599

全球肺炎治疗市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

Global Pneumonia Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年02月01日 | 出版商:

Value Market Research | 英文 230 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球肺炎治疗市场的需求预计将从2023年的44.4亿美元达到2032年近89.6亿美元的市场规模，2024-2032年研究期间的CAGR为8.12%。

肺炎治疗是指旨在解决肺炎的医学治疗和干预措施，肺炎是一种通常由细菌、病毒或真菌感染引起的发炎性肺部疾病。治疗方法可能包括抗生素、抗病毒药物、支持性治疗，严重情况下还需住院治疗。目标是消除病原体、缓解症状并促进呼吸恢復，确保患者获得最佳治疗效果。

市场动态

肺炎治疗市场受到呼吸道感染高发生率、人口老化、肺炎相关併发症持续存在等因素的影响。对肺炎认识的提高和早期诊断，加上治疗选择的进步，促进了市场的成长。对有效和有针对性的治疗方案（包括抗生素和疫苗）的需求在推动市场方面发挥着至关重要的作用。此外，COVID-19 大流行等传染病爆发的影响凸显了肺炎治疗和呼吸系统健康的重要性。专注于新型治疗方式和个人化医疗的持续研发工作也有助于扩大肺炎治疗市场。

该报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球肺炎治疗市场的各个细分市场进行了包容性评估。肺炎治疗产业的成长和趋势为本研究提供了整体方法。

市场区隔

肺炎治疗市场报告的这一部分透过在国家和地区层面进行分析，提供了有关细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按类型

细菌性肺炎
病毒性肺炎
霉菌性肺炎

按年龄段

孩子们
成人
老年科

依给药途径

口服
注射用
其他的

按药物类别

抗生素
抗病毒药物
抗真菌药物
皮质类固醇
其他（NSAIDs、止咳药等）

按配销通路

医院药房
零售药局
网路药局

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲肺炎治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。肺炎治疗市场的主要参与者包括阿斯特捷利康、诺华公司、艾伯维公司、梯瓦製药工业有限公司、辉瑞公司、赛诺菲、Lupin Pharmaceuticals, Inc.、Innoviva, Inc.、Wockhardt Ltd.、住友製药有限公司、该部分包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

简介 - 市场动态
市场驱动因素
市场限制
机会
产业动态
波特五力分析
市场吸引力分析
- 按类型分類的市场吸引力分析
- 按年龄组别分類的市场吸引力分析
- 按给药途径进行的市场吸引力分析
- 按药品类别分類的市场吸引力分析
- 按配销通路分類的市场吸引力分析
- 市场吸引力分析：按地区

第 4 章：价值链分析

价值链分析
原料分析
- 原料清单
- 原料厂商清单
- 主要原物料价格走势
潜在买家名单
行销管道
- 直效行销
- 间接行销
- 行销通路发展趋势

第 5 章：全球肺炎治疗市场分析：按类型

按类型概述
历史和预测数据
按类型分析
细菌性肺炎
病毒性肺炎
霉菌性肺炎

第 6 章：全球肺炎治疗市场分析：依年龄组别划分

依年龄组别概览
历史和预测数据
按年龄组分析
孩子们
成人
老年科

第 7 章：全球肺炎治疗市场分析：按给药途径

依给药途径概述
历史和预测数据
依给药途径分析
口服
注射用
其他的

第 8 章：全球肺炎治疗市场分析：依药物类别

按药物类别概述
历史和预测数据
按药物类别分析
抗生素
抗病毒药物
抗真菌药物
皮质类固醇
其他（非类固醇抗发炎药、止咳药等）

第 9 章：全球肺炎治疗市场分析：按分销管道

按配销通路分類的概览
历史和预测数据
按配销通路分析
医院药房
零售药局
网路药局

第 10 章：全球肺炎治疗市场分析：依地理位置

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 11 章：肺炎治疗公司的竞争格局

肺炎治疗市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 12 章：公司简介

公司股份分析
市场集中度
AstraZeneca

公司简介
公司收入
产品
最近的发展

Novartis AG

公司简介
公司收入
产品
最近的发展

AbbVie Inc.

公司简介
公司收入
产品
最近的发展

Teva Pharmaceutical Industries Ltd.

公司简介
公司收入
产品
最近的发展

Pfizer Inc.

公司简介
公司收入
产品
最近的发展

Sanofi

公司简介
公司收入
产品
最近的发展

Lupin Pharmaceuticals Inc.

公司简介
公司收入
产品
最近的发展

Innoviva Inc.

公司简介
公司收入
产品
最近的发展

Wockhardt Ltd.

公司简介
公司收入
产品
最近的发展

Sumitomo Pharma Co. Ltd.

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

简介目录图表

Product Code: VMR112113744

The global demand for Pneumonia Therapeutics Market is presumed to reach the market size of nearly USD 8.96 Billion by 2032 from USD 4.44 Billion in 2023 with a CAGR of 8.12% under the study period 2024 - 2032.

Pneumonia therapeutics refers to the medical treatments and interventions aimed at addressing pneumonia, an inflammatory lung condition typically caused by bacterial, viral, or fungal infections. Therapeutic approaches may include antibiotics, antiviral medications, supportive care, and, in severe cases, hospitalization. The goal is to eliminate the causative agent, alleviate symptoms, and promote respiratory recovery, ensuring optimal patient outcomes.

MARKET DYNAMICS

The Pneumonia therapeutics market is influenced by factors such as the high prevalence of respiratory infections, increasing aging populations, and the persistence of pneumonia-related complications. Rising awareness and early diagnosis of pneumonia, coupled with advancements in therapeutic options, contribute to the market's growth. The demand for effective and targeted treatment options, including antibiotics and vaccines, plays a crucial role in driving the market. Additionally, the impact of infectious disease outbreaks, such as the COVID-19 pandemic, highlights the importance of pneumonia therapeutics and respiratory health. Ongoing research and development efforts focusing on novel treatment modalities and personalized medicine also contribute to the expansion of the pneumonia therapeutics market.

The report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pneumonia therapeutics. The growth and trends of Pneumonia Therapeutics Industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the pneumonia therapeutics market report provides detailed data on the segments by analyzing them at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Bacterial Pneumonia
Viral Pneumonia
Fungal Pneumonia

By Age Group

Children
Adult
Geriatric

By Route Of Administration

Oral
Parenteral
Others

By Drug Class

Antibiotics
Antiviral Drugs
Antifungal Drugs
Corticosteroids
Others (NSAIDs, Cough Suppressant, Etc.)

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Pneumonia Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the pneumonia therapeutics market include AstraZeneca, Novartis AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi, Lupin Pharmaceuticals, Inc., Innoviva, Inc., Wockhardt Ltd., Sumitomo Pharma Co., Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PNEUMONIA THERAPEUTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Age Group
- 3.7.3 Market Attractiveness Analysis By Route of Administration
- 3.7.4 Market Attractiveness Analysis By Drug Class
- 3.7.5 Market Attractiveness Analysis By Distribution Channel
- 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY TYPE

5.1 Overview by Type
5.2 Historical and Forecast Data
5.3 Analysis by Type
5.4 Bacterial Pneumonia Historic and Forecast Sales by Regions
5.5 Viral Pneumonia Historic and Forecast Sales by Regions
5.6 Fungal Pneumonia Historic and Forecast Sales by Regions

6 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY AGE GROUP

6.1 Overview by Age Group
6.2 Historical and Forecast Data
6.3 Analysis by Age Group
6.4 Children Historic and Forecast Sales by Regions
6.5 Adult Historic and Forecast Sales by Regions
6.6 Geriatric Historic and Forecast Sales by Regions

7 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

7.1 Overview by Route of Administration
7.2 Historical and Forecast Data
7.3 Analysis by Route of Administration
7.4 Oral Historic and Forecast Sales by Regions
7.5 Parenteral Historic and Forecast Sales by Regions
7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS

8.1 Overview by Drug Class
8.2 Historical and Forecast Data
8.3 Analysis by Drug Class
8.4 Antibiotics Historic and Forecast Sales by Regions
8.5 Antiviral Drugs Historic and Forecast Sales by Regions
8.6 Antifungal Drugs Historic and Forecast Sales by Regions
8.7 Corticosteroids Historic and Forecast Sales by Regions
8.8 Others (NSAIDs, Cough suppressant, etc.) Historic and Forecast Sales by Regions

9 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

9.1 Overview by Distribution Channel
9.2 Historical and Forecast Data
9.3 Analysis by Distribution Channel
9.4 Hospital Pharmacies Historic and Forecast Sales by Regions
9.5 Retail Pharmacies Historic and Forecast Sales by Regions
9.6 Online Pharmacies Historic and Forecast Sales by Regions

10 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Data Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Data Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Data Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. South East Asia Sales Analysis
- 10.5.10. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Data Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Data Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE PNEUMONIA THERAPEUTICS COMPANIES

11.1. Pneumonia Therapeutics Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF PNEUMONIA THERAPEUTICS INDUSTRY

12.1. Company Share Analysis
12.2. Market Concentration Rate
12.3. AstraZeneca
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. Novartis AG
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. AbbVie Inc.
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. Teva Pharmaceutical Industries Ltd.
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. Pfizer Inc.
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. Sanofi
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. Lupin Pharmaceuticals Inc.
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. Innoviva Inc.
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments
12.11. Wockhardt Ltd.
- 12.11.1. Company Overview
- 12.11.2. Company Revenue
- 12.11.3. Products
- 12.11.4. Recent Developments
12.12. Sumitomo Pharma Co. Ltd.
- 12.12.1. Company Overview
- 12.12.2. Company Revenue
- 12.12.3. Products
- 12.12.4. Recent Developments